Quick Answer
China SXT Pharmaceuticals, Inc. reported Total Revenue of $1.93 million for fiscal year 2024.
China SXT Pharmaceuticals, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2024 | $1.93M | -2.2% |
| 2023 | $1.97M | -24.2% |
| 2022 | $2.60M | -45.5% |
| 2021 | $4.78M | -7.5% |
| 2020 | $5.16M | -26.4% |
| 2019 | $7.01M | -0.1% |
| 2018 | $7.02M | +43.8% |
| 2017 | $4.88M | — |
- China SXT Pharmaceuticals, Inc. showed a decrease of -2.2% in Total Revenue compared to the prior fiscal year.
- Over the 2017–2024 period, China SXT Pharmaceuticals, Inc.’s total revenue has declined by 60.5% (from $4.88 million to $1.93 million).
- The most recent figure is from China SXT Pharmaceuticals, Inc.’s fiscal year 2023 report (Form 20-F), filed with the SEC on August 13, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: